Table 3.

Association of CRY2 variants with NHL risk by B-cell subtype

GenotypeDLBCLFLCLL/SLLMZBL
Controls nCases nOR * (95% CI)Cases nOR * (95% CI)Cases nOR * (95% CI)Cases nOR * (95% CI)
rs11038689
    A/A or A/G495126904827
    G/G1761.41 (0.54–3.65)103.17 (1.39–7.19)52.75 (0.96–7.86)22.30 (0.50–10.61)
    P0.4840.0060.0600.285
rs11605924
    A/A or A/C36593793119
    C/C151390.98 (0.64–1.50)210.61 (0.36–1.04)120.72 (0.36–1.40)101.21 (0.54–2.70)
    P0.9310.0680.3290.643
rs2292912
    C/C or C/G489127975227
    G/G2940.53 (0.17–1.65)40.95 (0.31–2.93)10.27 (0.03–2.26)21.60 (0.34–7.60)
    P0.2740.9320.227
rs7123390
    G/G or G/A491124854527
    A/A2171.31 (0.54–3.16)143.67 (1.79–7.56)73.38 (1.35–8.45)21.86 (0.41–8.43)
    P0.547<0.0010.0090.423
rs1401417
    G/G or G/C503122954729
    C/C1492.67 (1.13–6.33)83.06 (1.24–7.54)64.23 (1.53–11.67)11.30 (0.16–10.33)
    P0.0260.0150.0050.806
  • * Adjusted for age (continuous), race, and family history of cancer in first- or second-degree relatives.